Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.46 |
| ▸ | AURKA | O14965 | 9/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279354 | 0.90 | NPC1 (0.48) | AURKAAURKBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4289180 | 0.88 | ITGB3 (0.46) | AURKAAURKB | |
| SCHEMBL4285654 | 0.88 | SMN1; SMN2 (0.47) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4279238 | 0.88 | FLT3 (0.44) | AURKAAURKBFGFR1MEN1KMT2A | |
| SCHEMBL4280877 | 0.88 | NPC1 (0.39) | AURKAAURKBMEN1NPC1MAPT | |
| SCHEMBL4287244 | 0.88 | ALDH1A1 (0.47) | AURKAMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4285338 | 0.86 | GAA (0.44) | TRPV4AURKAAURKBFGFR1MEN1 | |
| SCHEMBL4285294 | 0.86 | AURKA (0.38) | AURKAAURKBMEN1NPC1MAPT | |
| SCHEMBL4278068 | 0.86 | TNIK (0.38) | AURKAAURKBMEN1NPC1MAPT | |
| SCHEMBL4289169 | 0.85 | AURKA (0.42) | AURKAAURKBFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2009-05-28 | — | — | US | claimed |
| US-9012487-B2 | Bicyclo-pyrazoles active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-04-21 | — | — | US | disclosed |
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | MAP3K19, CDK2, MAP3K1 | TRPV4 3906/4885AURKA 42/4885AURKB 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.